Clinical Trials

Find a Trial

Trial Summary

Protocol No.EAY131/MATCH
Principal InvestigatorMiller, Kathy
Age GroupAdult
TitleMolecular Analysis for Therapy Choice (MATCH)
DescriptionThis phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors or lymphomas.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • Patients must have histologically documented solid tumors or histologically confirmed diagnosis of lymphoma that has progressed following at least one line of standard systemic therapy and/or for whose disease no standard treatment exists that has been shown to prolong survival
  • Patients must not currently be receiving any other investigational agents
For a full list of participation criteria, please visit
Applicable Disease SitesAny Site
Participating InstitutionsIU Health Arnett
    Indiana University (IU)
    • Eskenazi Hospital
    • Indiana University Hospital / IU Simon Cancer Center
    • Riley Hospital for Children
    • Spring Mill Medical Center
    Treatment TypeScreening
    ContactPhone: (317) 278-5632